Balancing the risks and rewards of live biotherapeutics

Affiliations

Comment

Colin Hill. Nat Rev Gastroenterol Hepatol. 2020 Mar.

. 2020 Mar;17(3):133-134.

doi: 10.1038/s41575-019-0254-3.

¹ APC Microbiome Ireland & School of Microbiology, University College Cork, Cork, Ireland. c.hill@ucc.ie.

No abstract available

Comment on

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. DeFilipp Z, et al. N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30. N Engl J Med. 2019. PMID: 31665575
Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients.
Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, Hinkle M, Lesho E, McGann P, McAdam AJ, Sandora TJ, Kishony R, Priebe GP. Yelin I, et al. Nat Med. 2019 Nov;25(11):1728-1732. doi: 10.1038/s41591-019-0626-9. Epub 2019 Nov 7. Nat Med. 2019. PMID: 31700189 Free PMC article.

1. DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019). - DOI
1. Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019). - DOI
1. Hill, C. Virulence or niche factors: what’s in a name? J. Bacteriol. 194, 5725–5727 (2012). - DOI
1. U.S. Food & Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. fda.gov https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologi... (2019).
1. Lai, C. Y. et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment. Pharmacol. Ther. 49, 354–363 (2019). - DOI